If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,548.00    -6.00 (-0.39%)
Bid:
1,544.00
Ask:
1,547.00
Spread: 3.00 (0.194%)
Market Cap: £3.26b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Annual Information Update

2 Aug 2010 12:16

RNS Number : 3618Q
Hikma Pharmaceuticals Plc
02 August 2010
 



 

 

Annual Information Update

LONDON, 2 August 2010. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date of Announcement

Headline of Announcement

14 May 2009

Interim Management Statement

14 May 2009

Result of AGM

19 May 2009

Director/PDMR Shareholding

29 June 2009

Director/PDMR Shareholding

5 August 2009

Total Voting Rights

27 August 2009

Half Yearly Report

1 October 2009

Total Voting Rights

1 October 2009

Additional Listing

16 October 2009

Director/PDMR Shareholding

20 October 2009

Blocklisting Interim Review

2 November 2009

Total Voting Rights

12 November 2009

Interim Management Statement

18 November 2009

Director/PDMR Shareholding

18 November 2009

Director/PDMR Shareholding

19 November 2009

Director/PDMR Shareholding

1 December 2009

Director/PDMR Shareholding

1 December 2009

Total Voting Rights

18 December 2009

Director/PDMR Shareholding

4 January 2010

Total Voting Rights

5 January 2010

Director/PDMR Shareholding

1 February 2010

Total Voting Rights

1 March 2010

Notice of Results

10 March 2010

Total Voting Rights

15 March 2010

Blocklisting of Shares

17 March 2010

Preliminary Announcement for 2009

23 March 2010

Director/PDMR Shareholding

30 March 2010

Hikma expands in the Tunisian market

1 April 2010

Blocklisting Six Monthly return

1 April 2010

Voting Rights & Capital

7 April 2010

Director/PDMR Shareholding

8 April 2010

Director/PDMR Shareholding

9 April 2010

Director/PDMR Shareholding

9 April 2010

Director/PDMR Shareholding

9 April 2010

Annual Financial Report

12 April 2010

Hikma expands in the Algerian market

20 April 2010

Director/PDMR Shareholding

23 April 2010

Director/PDMR Shareholding

5 May 2010

Voting Rights & Capital

13 May 2010

Interim Management Statement

13 May 2010

AGM Statement

26 July 2010

Voting Rights and Capital

All of the above announcements were also made by the Company via the NasdaqDubai stock exchange CANDI system. These announcements may be viewed and downloaded from the NasdaqDubai website (www.candi.nasdaq.com).

 

Documents filed with the Financial Services Authority

The Company has filed the following documents with the Financial Services Authority ("FSA") over the previous 12 months. These documents are available to be viewed via the UKLA's Document Viewing Facility at the Financial Services Authority, 25 the North Colonnade, London, E14 5HS or at the Company's registered office.

Date

Document

9 April 2010

Annual Report and Accounts 2009

9 April 2010

Notice of 2010 Annual General Meeting

9 April 2010

Proxy forms for the 2010 Annual General Meeting

9 April 2010

Sterling and Jordanian Dinar dividend election forms

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.

Date Filed

Form

Description

30 July 2010

SH01

31/05/10 statement of capital GBP 19326339

30 July 2010

SH01

30/04/10 statement of capital GBP 19313279

23 July 2010

SH01

31/03/10 statement of capital GBP 19260000

9 June 2010

AA

Group of companies' accounts made up to 31/12/09

8 June 2010

RES01

Alteration to memorandum and articles

8 June 2010

RES10

Authorised allotment of shares and debentures

8 June 2010

RES09

Authority to purchase shares other than from capital

8 June 2010

RES11

Disapplication of pre-emption rights

26 May 2010

RES10

Authorised allotment of shares and debentures

26 May 2010

RES01

Alteration to memorandum and articles

26 May 2010

RES11

Disapplication of pre-emption rights

19 April 2010

SH01

31/01/10 statement of capital GBP 19176400

19 April 2010

SH01

30/11/09 statement of capital GBP 19156490

19 April 2010

SH01

31/12/09 statement of capital GBP 19162760

16 April 2010

SH01

31/03/10 statement of capital GBP 19260000

15 October 2009

AD03

Register(s) moved to sail address

15 October 2009

AD02

Sail address created

29 September 2009

363a

Return made up to 08/09/09; bulk list available separately

24 September 2009

88(2)

AD 01/07/09-30/07/09 issued share capital GBP IC 18982880/18983480

24 September 2009

88(2)

AD 01/06/09-30/06/09 issued share capital GBP IC 18959440/18982880

24 September 2009

88(2)

AD 01/05/09-30/05/09 issued share capital GBP IC 18940080/18959440

24 September 2009

88(2)

AD 01/04/09-30/04/09 issued share capital GBP IC 18912440/18940080

24 September 2009

88(2)

AD 01/03/09 to 30/03/09 issued share capital GBP IC 18888160/18912440

25 July 2009

AA

Group of companies' accounts made up to 31/12/08

3 June 2009

RES10

Authorised allotment of shares and debentures

3 June 2009

RES13

Approve remuneration committee report 14/05/2009

3 June 2009

RES09

Authority to purchase shares other than from capital

3 June 2009

RES11

Disapplication of pre-emption rights

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk.

Further Information

Further information about Hikma Pharmaceuticals PLC can be found at our website www.hikma.com. Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

 

Henry Knowles Company Secretary 2 August 2010

- ENDS -

 

 

Enquiries:

 

Hikma Pharmaceuticals PLC

Henry Knowles

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

Investor Relations Director

 

+44 20 7399 2670

 

Financial Dynamics

Ben Atwell/ Julia Phillips

+44 20 7269 7242

 Jonathan Birt/ Matthew Cole

 

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUFLLFBBVFFBBE
Date   Source Headline
3rd Jun 20194:29 pmRNSTotal Voting Rights
17th May 20194:09 pmRNSResult of AGM
17th May 20193:33 pmRNSDirector/PDMR Shareholding
17th May 20197:00 amRNSTrading Statement
2nd May 20197:00 amRNSTotal Voting Rights
1st May 20199:00 amRNSHikma launches 100th injectable medicine in US
15th Apr 20194:26 pmRNSDirector/PDMR Shareholding
15th Apr 201912:23 pmRNSAnnual Financial Report
1st Apr 20195:42 pmRNSTotal Voting Rights
1st Apr 20195:11 pmRNSBlock listing Interim Review
18th Mar 20193:09 pmRNSDirector/PDMR Shareholding
15th Mar 201910:32 amRNSDirector/PDMR Shareholding
14th Mar 20199:14 amRNSDirector/PDMR Shareholding
13th Mar 20191:50 pmRNSDirector/PDMR Shareholding
13th Mar 20191:49 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSFinal Results
12th Mar 20197:00 amRNSDirectorate Change
1st Mar 20194:51 pmRNSTotal Voting Rights
28th Feb 20199:00 amRNSHikma establishes partnership with Melinta in MENA
27th Feb 20191:26 pmRNSBlock listing Interim Review
26th Feb 201911:08 amRNSNotice of Results
11th Feb 201910:11 amRNSDirector/PDMR Shareholding
1st Feb 20193:43 pmRNSTotal Voting Rights
29th Jan 20199:00 amRNSHikma launches Mitomycin for Injection
3rd Jan 20199:00 amRNSHikma announces agreement with Sciecure Pharma
19th Dec 20186:30 pmRNSShire
10th Dec 20189:00 amRNSHikma launches Clobazam
3rd Dec 201810:30 amRNSTotal Voting Rights
27th Nov 20189:00 amRNSHikma announces injectable licensing agreement
19th Nov 20189:00 amRNSHikma launches Triazolam Tablets
13th Nov 201811:15 amRNSHolding(s) in Company
8th Nov 20189:44 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSTrading Statement
1st Nov 201812:39 pmRNSTotal Voting Rights
16th Oct 20184:30 pmRNSBlock listing Interim Review
1st Oct 201810:53 amRNSTotal Voting Rights
1st Oct 201810:23 amRNSHolding(s) in Company
3rd Sep 201811:05 amRNSTotal Voting Rights
30th Aug 20189:58 amRNSHolding(s) in Company
28th Aug 201812:45 pmRNSHolding(s) in Company
22nd Aug 20189:41 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSHalf-year Report
23rd Jul 20189:00 amRNSNotice of Results
9th Jul 20189:00 amRNSHikma enters licensing partnership with Perrigo
2nd Jul 20184:56 pmRNSTotal Voting Rights
15th Jun 20183:24 pmRNSDirector/PDMR Shareholding
8th Jun 201811:50 amRNSDirector/PDMR Shareholding
4th Jun 201810:29 amRNSDirector/PDMR Shareholding
4th Jun 20189:00 amRNSHikma appoints Chief Transformation Officer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.